Institutes to Develop Bioterrorism Vaccines
The University of Maryland School of Medicine will lead a multischool effort with 16 research institutions to develop vaccines to protect against bioterroism. The Middle Atlantic region will receive a 5-year, $42-million grant from the National Institute of Allergy and Infectious Diseases. Aside from creating vaccines to protect against anthrax, smallpox, and West Nile virus, they will study antibodies that could produce short-term protection. The regional researchers will study viruses that cause hemorrhagic fevers (eg, Ebola and Marburg viruses), as well as targeting Escherichia coli and Shigella. Also, they will design better diagnostic tests and needle-free vaccinations for fast response to a biological attack or infectious disease outbreak.
?The events of 9-11 [in 2001] and the anthrax threats that followed made it clear that there are nefarious people out there,? said Myron M. Levine, MD, who is the regional leader. ?We have also come to realize that we are extremely vulnerable and to a great extent unprepared for biological attacks. It is crucial for us to develop preventive vaccines to protect ourselves.?
Articles in this issue
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Related Articles
- Advise Patients About Self-Care Measures to Treat Mild to Moderate GI Issues
September 18th 2025
- Evaluation of Pharmacist-Driven Penicillin Allergy Reconciliation
September 17th 2025
- Pharmacists Can Apply Their Expertise to the Medical Psilocybin Act
September 16th 2025
- From Curiosity to Clinical Impact: Shremo Msdi’s Path in Pharmacy Research
September 15th 2025